The Proof-of-Concept of MBA121, a Tacrine–Ferulic Acid Hybrid, for Alzheimer’s Disease Therapy
Abstract
:1. Introduction
2. Results and Discussion
2.1. Relief of Scopolamine-Induced Long-Term Memory Deficit in Mice by MBA121
2.2. Donepezil vs. MBA121: Locomotor Activity
2.3. Plate Count Aβ: Reduction of the Deposition of Aβ Plaques in MBA121 Treated APPswe/PSEN1ΔE9 Mice
3. Material and Methods
3.1. Behavioural Experiments
3.2. MBA121 Treatment in APPswe/PS1ΔE9 Mice
3.3. Tioflavin-S Staining
3.4. Statistical Analysis
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- World Health Organisation. Dementia; World Health Organization: Geneva, Switzerland, 2020. [Google Scholar]
- Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2021, 17, 327–406. [Google Scholar] [CrossRef] [PubMed]
- Caruso, P.; Signori, R.; Moretti, R. Small Vessel Disease to Subcortical Dementia: A Dynamic Model, Which Interfaces Aging, Cholinergic Dysregulation and the Neurovascular Unit 5. Vasc. Health Risk Manag. 2019, 15, 259–281. [Google Scholar] [CrossRef] [PubMed]
- Lupo, G.; Gaetani, S.; Cacci, E.; Biagioni, S.; Negri, R. Molecular Signatures of the Aging Brain: Finding the Links between Genes and Phenotypes 25. Neurotherapeutics 2019, 16, 543–553. [Google Scholar] [CrossRef] [PubMed]
- Nandi, A.; Counts, N.; Chen, S.; Seligman, B.; Tortorice, D.; Vigo, D.; Bloom, D.E. Global and Regional Projections of the Economic Burden of Alzheimer’s Disease and Related Dementias from 2019 to 2050: A Value of Statistical Life Approach. eClinicalMedicine 2022, 51, 101580. [Google Scholar] [CrossRef] [PubMed]
- Chen, X.Q.; Mobley, W.C. Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights from Alternative Hypotheses 1. Front. Neurosci. 2019, 13, 446. [Google Scholar] [CrossRef] [Green Version]
- Kumar, D.; Sharma, A.; Sharma, L. A Comprehensive Review of Alzheimer’s Association with Related Proteins: Pathological Role and Therapeutic Significance. Curr. Neuropharmacol. 2020, 18, 674–695. [Google Scholar] [CrossRef]
- Shi, M.; Chu, F.; Zhu, F.; Zhu, J. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab. Front. Aging Neurosci. 2022, 14, 870517. [Google Scholar] [CrossRef]
- Selkoe, D.J.; Hardy, J. The Amyloid Hypothesis of Alzheimer’s Disease at 25 Years. EMBO Mol. Med. 2016, 8, 595–608. [Google Scholar] [CrossRef]
- Hernández, F.; Llorens-Martín, M.; Bolós, M.; Pérez, M.; Cuadros, R.; Pallas-Bazarra, N.; Zabala, J.C.; Avila, J. New Beginnings in Alzheimer’s Disease: The Most Prevalent Tauopathy. J. Alzheimer’s Dis. 2018, 64, S529–S534. [Google Scholar] [CrossRef]
- Sayas, C.L.; Ávila, J. GSK-3 and Tau: A Key Duet in Alzheimer’s Disease. Cells 2021, 10, 72. [Google Scholar] [CrossRef]
- Serrano-Pozo, A.; Betensky, R.A.; Frosch, M.P.; Hyman, B.T. Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease. Am. J. Pathol. 2016, 186, 375–384. [Google Scholar] [CrossRef] [Green Version]
- De, S.B.; Karran, E. The Cellular Phase of Alzheimer’s Disease. Cell 2016, 164, 603–615. [Google Scholar]
- Ardura-Fabregat, A.; Boddeke, E.W.G.M.; Boza-Serrano, A.; Brioschi, S.; Castro-Gomez, S.; Ceyzeriat, K.; Dansokho, C.; Dierkes, T.; Gelders, G.; Heneka, M.T.; et al. Targeting Neuroinflammation to Treat Alzheimer’s Disease 3. CNS Drugs 2017, 31, 1057–1082. [Google Scholar] [CrossRef] [Green Version]
- Arriagada, P.V.; Growdon, J.H.; Hedley-Whyte, E.T.; Hyman, B.T. Neurofibrillary Tangles but Not Senile Plaques Parallel Duration and Severity of Alzheimer’s Disease. Neurology 1992, 42, 631–639. [Google Scholar] [CrossRef]
- Moreno-Grau, S.; Hernández, I.; Heilmann-Heimbach, S.; Ruiz, S.; Rosende-Roca, M.; Mauleón, A.; Vargas, L.; Rodríguez-Gómez, O.; Alegret, M.; Espinosa, A.; et al. Genome-Wide Significant Risk Factors on Chromosome 19 and the APOE Locus. Oncotarget 2018, 9, 24590–24600. [Google Scholar] [CrossRef] [Green Version]
- Wang, H.; Lo, M.-T.; Rosenthal, S.B.; Makowski, C.; Andreassen, O.A.; Salem, R.M.; McEvoy, L.K.; Fiecas, M.; Chen, C.-H. Similar Genetic Architecture of Alzheimer’s Disease and Differential APOE Effect Between Sexes. Front. Aging Neurosci. 2021, 13, 674318. [Google Scholar] [CrossRef]
- Seuma, M.; Faure, A.J.; Badia, M.; Lehner, B.; Bolognesi, B. The Genetic Landscape for Amyloid Beta Fibril Nucleation Accurately Discriminates Familial Alzheimer’s Disease Mutations. Elife 2021, 10, e63364. [Google Scholar] [CrossRef]
- Zekanowski, C.; Religa, D.; Graff, C.; Filipek, S.; Kuźnicki, J. Genetic Aspects of Alzheimer’s Disease. Acta Neurobiol. Exp. 2004, 64, 19–31. [Google Scholar]
- Schellenberg, G.; D’Souza, I.; Poorkaj, P. The Genetics of Alzheimer’s Disease. Curr. Psychiatry Rep. 2000, 2, 158–164. [Google Scholar] [CrossRef] [PubMed]
- Jankowsky, J.L.; Fadale, D.J.; Anderson, J.; Xu, G.M.; Gonzales, V.; Jenkins, N.A.; Copeland, N.G.; Lee, M.K.; Younkin, L.H.; Wagner, S.L.; et al. Mutant Presenilins Specifically Elevate the Levels of the 42 Residue Beta-Amyloid Peptide in Vivo: Evidence for Augmentation of a 42-Specific Gamma Secretase 3. Hum. Mol. Genet. 2004, 13, 159–170. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Takahashi, R.; Nagao, T.; Gouras, G. Plaque Formation and the Intraneuronal Accumulation of β-Amyloid in Alzheimer’s Disease. Pathol. Int. 2017, 67, 185–193. [Google Scholar] [CrossRef] [PubMed]
- Sindi, S.; Mangialasche, F.; Kivipelto, M. Advances in the Prevention of Alzheimer’s Disease. F1000Prime Rep. 2015, 7, 50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Folch, J.; Busquets, O.; Ettcheto, M.; Sánchez-López, E.; Pallàs, M.; Beas-Zarate, C.; Marin, M.; Casadesus, G.; Olloquequi, J.; Auladell, C.; et al. Experimental Models for Aging and Their Potential for Novel Drug Discovery. Curr. Neuropharmacol. 2018, 16, 1466–1483. [Google Scholar] [CrossRef] [PubMed]
- Haam, J.; Yakel, J.L. Cholinergic Modulation of the Hippocampal Region and Memory Function. J. Neurochem. 2017, 142, 111–121. [Google Scholar] [CrossRef] [Green Version]
- Davies, P.; Maloney, A.J.F. Selective Loss of Central Cholinergic Neurons in Alzheimer’s Disease. Lancet 1976, 308, 1403. [Google Scholar] [CrossRef] [PubMed]
- Burns, A.; Whitehause, P.; Arendt, T.; Förstil, H. Alzheimer’s Disease in Senile Dementia: Loss of Neurones in the Basal Forebrain. Whitehouse, P., Price, D., Struble, R., Clarke, A., Coyle, J. and Delong, M. Science (1982), 215, 1237-1239. Int. J. Geriatr. Psychiatry 1997, 12, 7–10. [Google Scholar] [CrossRef]
- Pi, R.; Mao, X.; Chao, X.; Cheng, Z.; Liu, M.; Duan, X.; Ye, M.; Chen, X.; Mei, Z.; Liu, P.; et al. Tacrine-6-Ferulic Acid, a Novel Multifunctional Dimer, Inhibits Amyloid-Beta-Mediated Alzheimer’s Disease-Associated Pathogenesis in Vitro and in Vivo 2. PLoS ONE 2012, 7, e31921. [Google Scholar] [CrossRef] [Green Version]
- Lagadic-Gossmann, D.; Rissel, M.; Le Bot, M.A.; Guillouzo, A. Toxic Effects of Tacrine on Primary Hepatocytes and Liver Epithelial Cells in Culture. Cell Biol. Toxicol. 1998, 14, 361–373. [Google Scholar] [CrossRef]
- Qizilbash, N.; Whitehead, A.; Higgins, J.; Wilcock, G.; Schneider, L.; Farlow, M. Cholinesterase Inhibition for Alzheimer Disease: A Meta-Analysis of the Tacrine Trials. Dementia Trialists’ Collaboration 4. JAMA 1998, 280, 1777–1782. [Google Scholar] [CrossRef]
- Ibrahim, M.M.; Gabr, M.T. Multitarget Therapeutic Strategies for Alzheimer’s Disease 1. Neural Regen. Res. 2019, 14, 437–440. [Google Scholar]
- Ismaili, L.; Refouvelet, B.; Benchekroun, M.; Brogi, S.; Brindisi, M.; Gemma, S.; Campiani, G.; Filipic, S.; Agbaba, D.; Esteban, G.; et al. Multitarget Compounds Bearing Tacrine- and Donepezil-like Structural and Functional Motifs for the Potential Treatment of Alzheimer’s Disease 17. Prog. Neurobiol. 2017, 151, 4–34. [Google Scholar] [CrossRef] [PubMed]
- Rani, A.; Singh, A.; Kaur, J.; Singh, G.; Bhatti, R.; Gumede, N.; Kisten, P.; Singh, P.; Sumanjit; Kumar, V. 1H-1,2,3-Triazole Grafted Tacrine-Chalcone Conjugates as Potential Cholinesterase Inhibitors with the Evaluation of Their Behavioral Tests and Oxidative Stress in Mice Brain Cells. Bioorg. Chem. 2021, 114, 105053. [Google Scholar] [CrossRef] [PubMed]
- Bartolini, M.; Marco-Contelles, J. Tacrines as Therapeutic Agents for Alzheimer’s Disease. IV. The Tacripyrines and Related Annulated Tacrines 2. Chem. Rec. 2019, 19, 927–937. [Google Scholar] [CrossRef] [PubMed]
- Romero, A.; Marco-Contelles, J.; Ramos, E. Highlights of ASS234: A Novel and Promising Therapeutic Agent for Alzheimer’s Disease Therapy 1. Neural Regen. Res. 2020, 15, 30–35. [Google Scholar] [CrossRef] [PubMed]
- Sun, X.; Zhang, P.; Pi, R.; Zhou, Y.; Deng, X.; Xie, Z.; Liao, Q. Determination of Tacrine-6-Ferulic Acid in Rat Plasma by LC-MS/MS and Its Application to Pharmacokinetics Study 33. Biomed. Chromatogr. 2014, 28, 1352–1359. [Google Scholar] [CrossRef]
- Huang, W.Y.; Chao, X.J.; Ouyang, Y.; Liu, A.M.; He, X.X.; Chen, M.H.; Wang, L.H.; Liu, J.; Yu, S.W.; Rapposelli, S.; et al. Tacrine-6-Ferulic Acid, a Novel Multifunctional Dimer against Alzheimer’s Disease, Prevents Oxidative Stress-Induced Neuronal Death through Activating Nrf2/ARE/HO-1 Pathway in HT22 Cells 1. CNS Neurosci. Ther. 2012, 18, 950–951. [Google Scholar] [CrossRef]
- Fang, L.; Kraus, B.; Lehmann, J.; Heilmann, J.; Zhang, Y.; Decker, M. Design and Synthesis of Tacrine-Ferulic Acid Hybrids as Multi-Potent Anti-Alzheimer Drug Candidates 4. Bioorg. Med. Chem. Lett. 2008, 18, 2905–2909. [Google Scholar] [CrossRef]
- Oset-Gasque, M.J.; Marco-Contelles, J. Tacrine-Natural-Product Hybrids for Alzheimer’s Disease Therapy. Curr. Med. Chem. 2018, 25, 4392–4400. [Google Scholar] [CrossRef]
- de los Ríos, C.; Marco-Contelles, J. Tacrines for Alzheimer’s Disease Therapy. III. The PyridoTacrines. Eur. J. Med. Chem. 2019, 166, 381–389. [Google Scholar] [CrossRef]
- Mori, T.; Koyama, N.; Guillot-Sestier, M.-V.; Tan, J.; Town, T. Ferulic Acid Is a Nutraceutical β-Secretase Modulator That Improves Behavioral Impairment and Alzheimer-like Pathology in Transgenic Mice. PLoS ONE 2013, 8, e55774. [Google Scholar] [CrossRef] [Green Version]
- Benchekroun, M.; Bartolini, M.; Egea, J.; Romero, A.; Soriano, E.; Pudlo, M.; Luzet, V.; Andrisano, V.; Jimeno, M.L.; Lopez, M.G.; et al. Novel Tacrine-Grafted Ugi Adducts as Multipotent Anti-Alzheimer Drugs: A Synthetic Renewal in Tacrine-Ferulic Acid Hybrids 1. ChemMedChem 2015, 10, 523–539. [Google Scholar] [CrossRef] [Green Version]
- Serrano, M.P.; Herrero-Labrador, R.; Futch, H.S.; Serrano, J.; Romero, A.; Fernandez, A.P.; Samadi, A.; Unzeta, M.; Marco-Contelles, J.; Martínez-Murillo, R. The Proof-of-Concept of ASS234: Peripherally Administered ASS234 Enters the Central Nervous System and Reduces Pathology in a Male Mouse Model of Alzheimer Disease. J. Psychiatry Neurosci. 2017, 42, 59–69. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Savonenko, A.; Xu, G.M.; Melnikova, T.; Morton, J.L.; Gonzales, V.; Wong, M.P.F.; Price, D.L.; Tang, F.; Markowska, A.L.; Borchelt, D.R. Episodic-like Memory Deficits in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease: Relationships to Beta-Amyloid Deposition and Neurotransmitter Abnormalities. Neurobiol. Dis. 2005, 18, 602–617. [Google Scholar] [CrossRef] [PubMed]
- Dawson, G.R.; Bentley, G.; Draper, F.; Rycroft, W.; Iversen, S.D.; Pagella, P.G. The Behavioral Effects of Heptyl Physostigmine, a New Cholinesterase Inhibitor, in Tests of Long-Term and Working Memory in Rodents 3. Pharmacol. Biochem. Behav. 1991, 39, 865–871. [Google Scholar] [CrossRef] [PubMed]
- Preston, G.C.; Brazell, C.; Ward, C.; Broks, P.; Traub, M.; Stahl, S.M. The Scopolamine Model of Dementia: Determination of Central Cholinomimetic Effects of Physostigmine on Cognition and Biochemical Markers in Man. J. Psychopharmacolo. 1988, 2, 67–79. [Google Scholar] [CrossRef] [PubMed]
- Võikar, V.; Stanford, S.C. The Open Field Test BT—Psychiatric Vulnerability, Mood, and Anxiety Disorders: Tests and Models in Mice and Rats; Harro, J., Ed.; Springer: New York, NY, USA, 2023; pp. 9–29. ISBN 978-1-0716-2748-8. [Google Scholar]
- Lisman, J.; Buzsáki, G.; Eichenbaum, H.; Nadel, L.; Ranganath, C.; Redish, A.D. Viewpoints: How the Hippocampus Contributes to Memory, Navigation and Cognition. Nat. Neurosci. 2017, 20, 1434–1447. [Google Scholar] [CrossRef] [PubMed]
- Janus, C.; Flores, A.Y.; Xu, G.; Borchelt, D.R. Behavioral Abnormalities in APPSwe/PS1dE9 Mouse Model of AD-like Pathology: Comparative Analysis across Multiple Behavioral Domains 2. Neurobiol. Aging 2015, 36, 2519–2532. [Google Scholar] [CrossRef]
- Bussière, T.; Bard, F.; Barbour, R.; Grajeda, H.; Guido, T.; Khan, K.; Schenk, D.; Games, D.; Seubert, P.; Buttini, M. Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive Aβ Immunotherapy on Their Clearance. Am. J. Pathol. 2004, 165, 987–995. [Google Scholar] [CrossRef]
- Wang, L.; Esteban, G.; Ojima, M.; Bautista-Aguilera, O.M.; Inokuchi, T.; Moraleda, I.; Iriepa, I.; Samadi, A.; Youdim, M.B.; Romero, A.; et al. Donepezil + Propargylamine + 8-Hydroxyquinoline Hybrids as New Multifunctional Metal-Chelators, ChE and MAO Inhibitors for the Potential Treatment of Alzheimer’s Disease 3. Eur. J. Med. Chem. 2014, 80, 543–561. [Google Scholar] [CrossRef] [Green Version]
- Jankowsky, J.L.; Slunt, H.H.; Ratovitski, T.; Jenkins, N.A.; Copeland, N.G.; Borchelt, D.R. Co-Expression of Multiple Transgenes in Mouse CNS: A Comparison of Strategies. Biomol. Eng. 2001, 17, 157–165. [Google Scholar] [CrossRef]
- Belinson, H.; Lev, D.; Masliah, E.; Michaelson, D.M. Activation of the Amyloid Cascade in Apolipoprotein E4 Transgenic Mice Induces Lysosomal Activation and Neurodegeneration Resulting in Marked Cognitive Deficits. J. Neurosci. 2008, 28, 4690–4701. [Google Scholar] [CrossRef] [Green Version]
- Jiao, L.; Du, X.; Jia, F.; Li, Y.; Zhu, D.; Tang, T.; Jiao, Q.; Jiang, H. Early Low-Dose Ghrelin Intervention via Miniosmotic Pumps Could Protect against the Progressive Dopaminergic Neuron Loss in Parkinson’s Disease Mice. Neurobiol. Aging 2021, 101, 70–78. [Google Scholar] [CrossRef]
- Ly, P.T.T.; Cai, F.; Song, W. Detection of Neuritic Plaques in Alzheimer’s Disease Mouse Model. J. Vis. Exp. 2011, 53, e2831. [Google Scholar] [CrossRef] [Green Version]
- Paxinos, G.; Franklin, K. The Mouse Brain in Stereotaxic Coordinates; Academic Press: Cambridge, MA, USA, 2008; ISBN 9780123742445. [Google Scholar]
- Bubley, A.; Erofeev, A.; Gorelkin, P.; Beloglazkina, E.; Majouga, A.; Krasnovskaya, O. Tacrine-Based Hybrids: Past, Present, and Future. Int. J. Mol. Sci. 2023, 24, 1717. [Google Scholar] [CrossRef]
- Chen, Y.; Sun, J.; Fang, L.; Liu, M.; Peng, S.; Liao, H.; Lehmann, J.; Zhang, Y. Tacrine-Ferulic Acid-Nitric Oxide (NO) Donor Trihybrids as Potent, Multifunctional Acetyl- and Butyrylcholinesterase Inhibitors 16. J. Med. Chem. 2012, 55, 4309–4321. [Google Scholar] [CrossRef]
- Fu, Y.; Mu, Y.; Lei, H.; Wang, P.; Li, X.; Leng, Q.; Han, L.; Qu, X.; Wang, Z.; Huang, X. Design, Synthesis and Evaluation of Novel Tacrine-Ferulic Acid Hybrids as Multifunctional Drug Candidates against Alzheimer’s Disease. Molecules 2016, 21, 1338. [Google Scholar] [CrossRef] [Green Version]
- Zhu, J.; Yang, H.; Chen, Y.; Lin, H.; Li, Q.; Mo, J.; Bian, Y.; Pei, Y.; Sun, H. Synthesis, Pharmacology and Molecular Docking on Multifunctional Tacrine-Ferulic Acid Hybrids as Cholinesterase Inhibitors against Alzheimer’s Disease. J. Enzyme Inhib. Med. Chem. 2018, 33, 496–506. [Google Scholar] [CrossRef] [Green Version]
- Fang, L.; Appenroth, D.; Decker, M.; Kiehntopf, M.; Lupp, A.; Peng, S.; Fleck, C.; Zhang, Y.; Lehmann, J. NO-Donating Tacrine Hybrid Compounds Improve Scopolamine-Induced Cognition Impairment and Show Less Hepatotoxicity. J. Med. Chem. 2008, 51, 7666–7669. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Zhu, J.; Mo, J.; Yang, H.; Jiang, X.; Lin, H.; Gu, K.; Pei, Y.; Wu, L.; Tan, R.; et al. Synthesis and Bioevaluation of New Tacrine-Cinnamic Acid Hybrids as Cholinesterase Inhibitors against Alzheimer’s Disease 4. J. Enzyme Inhib. Med. Chem. 2018, 33, 290–302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Borchelt, D.R.; Ratovitski, T.; van Lare, J.; Lee, M.K.; Gonzales, V.; Jenkins, N.A.; Copeland, N.G.; Price, D.L.; Sisodia, S.S. Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins. Neuron 1997, 19, 939–945. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Unzeta, M.; Esteban, G.; Bolea, I.; Fogel, W.A.; Ramsay, R.R.; Youdim, M.B.; Tipton, K.F.; Marco-Contelles, J. Multi-Target Directed Donepezil-Like Ligands for Alzheimer’s Disease 1. Front. Neurosci. 2016, 10, 205. [Google Scholar] [CrossRef] [Green Version]
- Pattanashetti, L.A.; Taranalli, A.D.; Parvatrao, V.; Malabade, R.H.; Kumar, D. Evaluation of Neuroprotective Effect of Quercetin with Donepezil in Scopolamine-Induced Amnesia in Rats 2. Indian J. Pharmacol. 2017, 49, 60–64. [Google Scholar] [PubMed]
- Chen, W.; Yeong, K. Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer’s Disease. CNS Neurol. Disord. Drug Targets 2020, 19, 85–93. [Google Scholar] [CrossRef]
- Lenz, R.A.; Baker, J.D.; Locke, C.; Rueter, L.E.; Mohler, E.G.; Wesnes, K.; bi-Saab, W.; Saltarelli, M.D. The Scopolamine Model as a Pharmacodynamic Marker in Early Drug Development 1. Psychopharmacology 2012, 220, 97–107. [Google Scholar] [CrossRef] [PubMed]
- Bali, Z.K.; Bruszt, N.; Tadepalli, S.A.; Csurgyok, R.; Nagy, L.V.; Tompa, M.; Hernadi, I. Cognitive Enhancer Effects of Low Memantine Doses Are Facilitated by an Alpha7 Nicotinic Acetylcholine Receptor Agonist in Scopolamine-Induced Amnesia in Rats. Front. Pharmacol. 2019, 10, 73. [Google Scholar] [CrossRef] [Green Version]
- Alves, S.; Churlaud, G.; Audrain, M.; Michaelsen-Preusse, K.; Fol, R.; Souchet, B.; Braudeau, J.; Korte, M.; Klatzmann, D.; Cartier, N. Interleukin-2 Improves Amyloid Pathology, Synaptic Failure and Memory in Alzheimer’s Disease Mice. Brain 2017, 140, 826–842. [Google Scholar] [CrossRef]
- Serrano-Pozo, A.; Frosch, M.P.; Masliah, E.; Hyman, B.T. Neuropathological Alterations in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2011, 1, a006189. [Google Scholar] [CrossRef] [Green Version]
- Babcock, K.R.; Page, J.S.; Fallon, J.R.; Webb, A.E. Adult Hippocampal Neurogenesis in Aging and Alzheimer’s Disease. Stem Cell Rep. 2021, 16, 681–693. [Google Scholar] [CrossRef]
- Braak, H.; Alafuzoff, I.; Arzberger, T.; Kretzschmar, H.; Del Tredici, K. Staging of Alzheimer Disease-Associated Neurofibrillary Pathology Using Paraffin Sections and Immunocytochemistry. Acta Neuropathol. 2006, 112, 389–404. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rodríguez-Ruiz, E.R.; Herrero-Labrador, R.; Fernández-Fernández, A.P.; Serrano-Masa, J.; Martínez-Montero, J.A.; González-Nieto, D.; Hana-Vaish, M.; Benchekroun, M.; Ismaili, L.; Marco-Contelles, J.; et al. The Proof-of-Concept of MBA121, a Tacrine–Ferulic Acid Hybrid, for Alzheimer’s Disease Therapy. Int. J. Mol. Sci. 2023, 24, 12254. https://doi.org/10.3390/ijms241512254
Rodríguez-Ruiz ER, Herrero-Labrador R, Fernández-Fernández AP, Serrano-Masa J, Martínez-Montero JA, González-Nieto D, Hana-Vaish M, Benchekroun M, Ismaili L, Marco-Contelles J, et al. The Proof-of-Concept of MBA121, a Tacrine–Ferulic Acid Hybrid, for Alzheimer’s Disease Therapy. International Journal of Molecular Sciences. 2023; 24(15):12254. https://doi.org/10.3390/ijms241512254
Chicago/Turabian StyleRodríguez-Ruiz, Emelina R., Raquel Herrero-Labrador, Ana P. Fernández-Fernández, Julia Serrano-Masa, José A. Martínez-Montero, Daniel González-Nieto, Mayuri Hana-Vaish, Mohamed Benchekroun, Lhassane Ismaili, José Marco-Contelles, and et al. 2023. "The Proof-of-Concept of MBA121, a Tacrine–Ferulic Acid Hybrid, for Alzheimer’s Disease Therapy" International Journal of Molecular Sciences 24, no. 15: 12254. https://doi.org/10.3390/ijms241512254